Evidence map›Paper›PMID 17601626›Full record

SynthesisDiabetes research and clinical practice2007

Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies.

Hertzel C Gerstein, Pasqualina Santaguida, Parminder Raina, Katherine M Morrison, Cynthia Balion, Dereck Hunt, Hossein Yazdi, Lynda Booker

4 registry-linked trialsAbstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Diabetes research and clinical practice, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 252 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 13 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06767774 phase4recruitingstarted 2025, after this paper: background citation

Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With Atherosclerotic Cardiovascular Disease

Ran2025Enrolled2,000Registered outcomes13Posted comparisons0ConditionsASCVD, Diabetes, StatinArmsCombination therapy, High intensity statin monotherapy
PMID 29263150PMID 23704171PMID 21693744PMID 20167359PMID 10333939PMID 17559928PMID 12186811PMID 12087009PMID 11270938PMID 3358991PMID 31518657PMID 31504418other papers from this trial
Open the trial in the graph
NCT03249077 completednot on this mapstarted 2017, after this paper: background citation

Evaluating the Implementation of the Diabetes Prevention Program in an Integrated Health System

TypeobservationalSponsorKaiser PermanenteRan2017 to 2021Enrolled8,198ConditionsDiabetesArmsDigital DPP, In-person DPP, DPP not enrolled
NCT05755555 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Testing the Effectiveness of Different Messaging Approaches to Increase Doctor Visits to Confirm or Exclude a Diagnosis of Prediabetes or Diabetes Amongst Individuals With Risk Factors for Diabetes: A Randomised, Controlled Trial

TypeinterventionalSponsorWits Health Consortium (Pty) LtdRan2022 to 2023Enrolled5,000ConditionsType 2 Diabetes, Pre-diabetesArmsVisit a doctor
NCT07252700 narecruitingnot on this mapstarted 2025, after this paper: background citation

Preventing Diabetes: Impact of an EMR-Based Intervention for Enhanced Pre-Diabetes Management in Primary Care

TypeinterventionalSponsorLynette GohRan2025 to 2028Enrolled6,000ConditionsPre Diabetes, Diabetes (DM)ArmsElectronic Medical Record-Based Clinical Decision Support
3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 13 syntheses or guidelines pooled it, 570 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.American journal of preventive medicine · 2022 · on this map
    Pooled it
  4. Prevalence of Type 2 Diabetes in South Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Marine Oil fromNutrients · 2022
    Trial
  20. Trial

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hertzel C GersteinDepartment of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. gerstein@mcmaster.ca
Pasqualina Santaguida
Parminder Raina
Katherine M Morrison
Cynthia Balion
Dereck Hunt
Hossein Yazdi
Lynda Booker
Hamilton Health Sciences · CAMcMaster University · CA

Funding

PHS HHS 290-02-0020
6 · The paper itself

Abstract

backgroundSeveral estimates of the risk of progression to diabetes in people with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) have been reported.

objectiveTo provide an estimate of the risk of progression to diabetes and regression to normoglycemia in these populations.

designSystematic overview and meta-analysis of prospective cohort studies published from 1979 until 2004.

settingGlobal cohort studies. PATIENTS: People with IFG or IGT detected by a screening oral glucose tolerance test. MEASUREMENTS: Fasting and post-load plasma glucose levels.

resultsThe absolute annual incidence of diabetes in individuals with various categories of IFG or IGT varied from 5 to 10%. Compared to normoglycemic people the meta-analyzed relative risk and 95% confidence interval for diabetes was: 6.35 (4.87-7.82) in people with IGT; 5.52 (3.13-7.91) in people with isolated IGT; 4.66 (2.47-6.85) in people with IFG; 7.54 (4.63-10.45) in people with isolated IFG; and 12.13 (4.27-20.00) in people with both IFG and IGT. People with IGT were 0.33 times as likely to be normoglycemic after 1 year compared to people with normal glucose tolerance (95% CI 0.23-0.43). LIMITATIONS: Studies that used differing criteria for IFG and IGT were included, and participants were classified on the basis of only one test.

conclusionIFG and IGT are associated with similar, high relative risk for incident diabetes. The combined abnormality of IFG plus IGT is associated with the highest relative risk.

Indexed as

Blood GlucoseDiabetes MellitusGlucose IntoleranceHumansIncidenceReference ValuesRiskBlood Glucose

Identifiers

PMID17601626
OpenAlexW1978897192

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.